Conspiracy Theory Posited Over Shire’s Withdrawal Of BLA For Fabry Disease Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Knowledge Ecology International suggests Shire pulled its Replagal BLA in return for rights to Mount Sinai School of Medicine patent that could have blocked sales in Europe; asks FTC to investigate “possible conspiracy” between school, Shire and Sanofi.
You may also be interested in...
Shire Withdraws Replagal BLA Rather Than Conduct Lengthy Trials – Updated
Distributed free of charge to U.S. patients with Genzyme’s Fabrazyme in short supply, Replagal seemed destined for quick approval, but FDA has signalled otherwise.
Employee’s Decoy Laptop Did Not Trick Pfizer Security, Trade Secret Suit Says
Pfizer alleges its associate director of statistics transferred 12,000 files from her company laptop ahead of move to Xencor. Company seeks a temporary restraining order to prevent her from disclosing confidential information, including information on Pfizer’s COVID-19 vaccine and monoclonal antibodies for treatment of cancer.
Lilly’s Alzheimer’s Drug Will Get ‘Easier Ride’ Than Aduhelm But Does Not Show Clinical Benefit, Prof Says
Harsh assessment of Lilly’s Phase II study by UCL and UCSF professors suggests donanemab may face same hurdles as Biogen’s Aduhelm. Lilly exec says the drug slowed disease progression by six months, but UCL prof says that won’t make a difference.